Atea Pharmaceuticals Q2 EPS $0.02 Up From $(0.99) YoY
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of $0.02 per share. This is a 102.02 percent increase over losses of $(0.99) per share from the same period last year.
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Understanding Atea Pharmaceuticals’s Unusual Options Activity
On Monday, shares of Atea Pharmaceuticals (NASDAQ:AVIR) saw unusual options activity. After the option alert, the stock price moved up to $32.99.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Atea Pharmaceuticals Announces Interim Results From Phase 2 Study Of AT-527 Showing ‘Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting’
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting
AT-527 is Being Studied in Multiple Clinical Studies, Including
Atea Pharmaceuticals Shares Spike Higher After The New York Times Reports U.S. Considering Back Co’s COVID Drugs
https://www.nytimes.com/2021/06/17/health/covid-pill-antiviral.html
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ:AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its…
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche; Expects To Receive A Related Payment Of $50M
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it